Major Shareholder Sells Millions in Zentalis Pharmaceuticals Stock!
I'm PortAI, I can summarize articles.
Matrix Capital Management Company, LP sold 7,500,000 shares of Zentalis Pharmaceuticals (ZNTL) for $9,975,000 on December 15, 2025. Zentalis repurchased these shares at $1.33 each. Despite financial challenges and weak technical indicators, there is cautious optimism due to positive clinical developments, particularly azenosertib's potential in treating aggressive cancers. Analysts rate the stock as Hold, with Spark's AI Analyst rating it Neutral. ZNTL's YTD price performance is -53.33%, with a current market cap of $101.2M.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments